LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.68 USD
-0.06 (-3.22%)
Updated Sep 12, 2024 03:59 PM ET
After-Market: $1.68 0.00 (-0.24%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LVTX 1.68 -0.06(-3.22%)
Will LVTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LVTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LVTX
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
LVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates
Other News for LVTX
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
LAVA Reports Second Quarter 2024 Financial Results and Business Update
LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.03
LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Underpin Buy Rating